The 36-month beta value for HOTH is also noteworthy at 0.58. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for HOTH is 13.08M, and at present, short sellers hold a 1.33% of that float. The average trading volume of HOTH on March 18, 2025 was 9.33M shares.
HOTH) stock’s latest price update
Hoth Therapeutics Inc (NASDAQ: HOTH)’s stock price has plunge by -1.71relation to previous closing price of 1.17. Nevertheless, the company has seen a 1.77% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-18 that New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours. Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays.
HOTH’s Market Performance
HOTH’s stock has risen by 1.77% in the past week, with a monthly rise of 1.77% and a quarterly rise of 35.77%. The volatility ratio for the week is 7.93% while the volatility levels for the last 30 days are 11.52% for Hoth Therapeutics Inc The simple moving average for the last 20 days is 8.49% for HOTH stock, with a simple moving average of 20.66% for the last 200 days.
Analysts’ Opinion of HOTH
Many brokerage firms have already submitted their reports for HOTH stocks, with The Benchmark Company repeating the rating for HOTH by listing it as a “Speculative Buy.” The predicted price for HOTH in the upcoming period, according to The Benchmark Company is $10 based on the research report published on October 15, 2019 of the previous year 2019.
HOTH Trading at -6.25% from the 50-Day Moving Average
After a stumble in the market that brought HOTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.74% of loss for the given period.
Volatility was left at 11.52%, however, over the last 30 days, the volatility rate increased by 7.93%, as shares surge +3.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +50.63% upper at present.
During the last 5 trading sessions, HOTH rose by +2.65%, which changed the moving average for the period of 200-days by +0.87% in comparison to the 20-day moving average, which settled at $1.0605. In addition, Hoth Therapeutics Inc saw 53.72% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HOTH starting from Knie Robb, who purchase 25,000 shares at the price of $0.67 back on Aug 16 ’24. After this action, Knie Robb now owns 58,131 shares of Hoth Therapeutics Inc, valued at $16,750 using the latest closing price.
Stock Fundamentals for HOTH
Current profitability levels for the company are sitting at:
- -126.48 for the present operating margin
- 0.5 for the gross margin
The net margin for Hoth Therapeutics Inc stands at -126.1. The total capital return value is set at -1.0. Equity return is now at value -83.41, with -73.63 for asset returns.
Based on Hoth Therapeutics Inc (HOTH), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -237.28. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -808.82.
Currently, EBITDA for the company is -0.15 million with net debt to EBITDA at 1.46. When we switch over and look at the enterprise to sales, we see a ratio of 124.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.16.
Conclusion
In summary, Hoth Therapeutics Inc (HOTH) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
